← Back to Screener
Tilray Brands, Inc. Common Stock (TLRY)
Price$4.94
Value ScoreB
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-47.16%
Price vs S&P 500 (4W)-11.14%
VGM Score56.70
Market Capitalization$590.84M
All Metrics
Book Value / Share (Quarterly)$13.36
P/TBV (Annual)0.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.34%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)-53.45%
Gross Margin (TTM)27.68%
Net Profit Margin (TTM)-156.67%
EPS (TTM)$-1.95
10-Day Avg Trading Volume3.64M
EPS Excl Extra (TTM)$-1.95
Revenue Growth (5Y)31.30%
EPS (Annual)$-2.46
ROI (Annual)-120.53%
Gross Margin (Annual)29.29%
Net Profit Margin (5Y Avg)-135.29%
Cash / Share (Quarterly)$1.89
Revenue Growth QoQ (YoY)11.28%
ROA (Last FY)-105.42%
Revenue Growth TTM (YoY)3.82%
EBITD / Share (TTM)$-4.45
ROE (5Y Avg)-42.94%
Operating Margin (TTM)-173.67%
Cash Flow / Share (Annual)$-0.12
P/B Ratio0.38x
P/B Ratio (Quarterly)0.57x
Net Income / Employee (Annual)$-769,400
EV / Revenue (TTM)0.79x
Net Interest Coverage (TTM)-47.45x
ROA (TTM)-64.57%
EV / EBITDA (TTM)5.90x
EPS Incl Extra (Annual)$-2.46
Current Ratio (Annual)2.46x
Quick Ratio (Quarterly)1.50x
3-Month Avg Trading Volume4.10M
52-Week Price Return27.32%
Revenue / Employee (TTM)$302,000
Tangible BV / Share (Quarterly)$13.16
P/S Ratio (Annual)0.72x
Asset Turnover (Annual)0.40x
52-Week High$23.20
Operating Margin (5Y Avg)-128.28%
EPS Excl Extra (Annual)$-2.46
CapEx CAGR (5Y)-5.91%
Tangible BV CAGR (5Y)51.38%
26-Week Price Return-39.24%
Quick Ratio (Annual)1.37x
13-Week Price Return-30.03%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)2.79x
Enterprise Value$680.65M
Revenue / Share Growth (5Y)-11.19%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-9.59%
Revenue / Employee (Annual)$289,000
Inventory Turnover (Annual)2.22x
Pretax Margin (Annual)-280.33%
Cash / Share (Annual)$0.24
3-Month Return Std Dev62.79%
Gross Margin (5Y Avg)24.73%
Net Income / Employee (TTM)$-473,100
ROE (Last FY)-144.68%
Net Interest Coverage (Annual)-10.53x
EPS Basic Excl Extra (Annual)$-2.46
P/FCF (TTM)80.25x
Receivables Turnover (TTM)7.74x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-1.95
Receivables Turnover (Annual)7.36x
ROI (TTM)-72.87%
P/S Ratio (TTM)0.69x
Pretax Margin (5Y Avg)-136.10%
Revenue / Share (Annual)$0.92
Tangible BV / Share (Annual)$1.40
Price vs S&P 500 (52W)2.95%
Year-to-Date Return-45.29%
5-Day Price Return-10.02%
EPS Normalized (Annual)$-2.46
ROA (5Y Avg)-31.96%
Net Profit Margin (Annual)-266.25%
Month-to-Date Return-10.34%
Cash Flow / Share (TTM)$-2.01
EBITD / Share (Annual)$-2.46
Operating Margin (Annual)-277.93%
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-36.12%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-1.95
P/TBV (Quarterly)0.58x
P/B Ratio (Annual)0.29x
Inventory Turnover (TTM)2.23x
Pretax Margin (TTM)-169.76%
Book Value / Share (Annual)$1.43
Price vs S&P 500 (13W)-38.28%
Beta1.92x
Revenue / Share (TTM)$7.62
ROE (TTM)-86.90%
52-Week Low$3.51
vGradeB
gGradeB
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.53
3.59
3.65
3.65
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLRYTilray Brands, Inc. Common Stock | B | B | D | $4.94 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $23.55 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.74 |
| CGCCanopy Growth Corporation Common Shares | C | D | C | $1.03 |
| USNAUSANA Health Sciences Inc | B | D | C | $18.03 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.45 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.42 |
| ACBAurora Cannabis Inc. Common Shares | B | C | C | $3.38 |
| MDWDMediWound Ltd. | D | F | D | $14.18 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.87 |
| BTMDBiote Corp. Class A Common Stock | B | D | C | $2.34 |
About
Tilray is a Canadian cannabis producer cultivating and distributing medical and recreational cannabis products. The company generates revenue primarily from the Canadian market and international medical cannabis exports, with U.S. operations concentrated in alcohol.